Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2021 Publisher: RPH Pharmaceuticals AB, Box 603, 101 32 Stockholm, Sweden
Betnesol 4mg/ml Solution for injection.
Betamethasone 4mg/ml Solution for injection.
| Pharmaceutical Form |
|---|
|
Solution for injection. 1ml ampoules containing a clear colourless or pale yellow solution. |
Each ampoule contains 5.3mg of betamethasone sodium phosphate equivalent to 4mg betamethasone in 1ml of sterile aqueous solution.
Excipients with known effect: Sodium Metabisulphite contains 0.100% w/v
Also contains approximately 0.678mg sodium per ml.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Betamethasone |
Betamethasone is a glucocorticoid which is about eight to ten times as active as prednisolone on a weight-for-weight basis. Betamethasone has anti-inflammatory, antipruritic, and vasoconstrictive properties. |
| List of Excipients |
|---|
|
Disodium edetate |
1ml clear, one-point cut (OPC) colourless glass Type 1 Ph Eur ampoules packed in cartons of 5 ampoules.
RPH Pharmaceuticals AB, Box 603, 101 32 Stockholm, Sweden
PL 36301/0054
22nd December 1992
| Drug | Countries | |
|---|---|---|
| BETNESOL | Canada, France, Ireland, Israel, Netherlands, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
